inclusion criteria: * male or female outpatients at least 12 years of age * presence of clinical signs and/or symptoms consistent with worsening or stable mild or moderate covid-19 (one of the following is required): 1. presence of at least two respiratory symptom domains (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro or 2. presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro with pulse rate ≥90 or 3. presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro with respiratory rate ≥16 and patient reported assessment that symptoms are present, the symptoms are not consistent with the subject's usual health, the symptoms interfere with daily activities, and the symptoms have worsened or remained the same relative to the previous day, as confirmed by responses to questions in the screening flu-pro. * onset of symptoms no more than 72 hours before enrollment in the trial. onset of symptoms is defined as the earlier of the first time at which the subject experienced subjective fever or any respiratory symptom (head, throat, nose, chest, or cough symptoms). * willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of the subject diary and all protocol procedures.

inclusion criteria: * male or female outpatients at least 12 years of age * presence of clinical signs and/or symptoms consistent with worsening or stable mild or moderate covid-19 (one of the following is required): 1. presence of at least two respiratory symptom domains (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro or 2. presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro with pulse rate ≥90 or 3. presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro with respiratory rate ≥16 and patient reported assessment that symptoms are present, the symptoms are not consistent with the subject's usual health, the symptoms interfere with daily activities, and the symptoms have worsened or remained the same relative to the previous day, as confirmed by responses to questions in the screening flu-pro. * onset of symptoms no more than 72 hours before enrollment in the trial. onset of symptoms is defined as the earlier of the first time at which the subject experienced subjective fever or any respiratory symptom (head, throat, nose, chest, or cough symptoms). * willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of the subject diary and all protocol procedures.

inclusion criteria: male or female outpatients at least 12 years of age presence of clinical signs and/or symptoms consistent with worsening or stable mild or moderate covid-19 (one of the following is required): presence of at least two respiratory symptom domains (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro or presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro with pulse rate ≥90 or presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro with respiratory rate ≥16 and patient reported assessment that symptoms are present, the symptoms are not consistent with the subject's usual health, the symptoms interfere with daily activities, and the symptoms have worsened or remained the same relative to the previous day, as confirmed by responses to questions in the screening flu-pro. onset of symptoms no more than 72 hours before enrollment in the trial. onset of symptoms is defined as the earlier of the first time at which the subject experienced subjective fever or any respiratory symptom (head, throat, nose, chest, or cough symptoms). willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of the subject diary and all protocol procedures.

inclusion criteria: male or female outpatients at least 12 years of age presence of clinical signs and/or symptoms consistent with worsening or stable mild or moderate covid-19 (one of the following is required): presence of at least two respiratory symptom domains (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro or presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro with pulse rate ≥90 or presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro with respiratory rate ≥16 and patient reported assessment that symptoms are present, the symptoms are not consistent with the subject's usual health, the symptoms interfere with daily activities, and the symptoms have worsened or remained the same relative to the previous day, as confirmed by responses to questions in the screening flu-pro. onset of symptoms no more than 72 hours before enrollment in the trial. onset of symptoms is defined as the earlier of the first time at which the subject experienced subjective fever or any respiratory symptom (head, throat, nose, chest, or cough symptoms). willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of the subject diary and all protocol procedures.

inclusion criteria: - male or female outpatients at least 12 years of age - presence of clinical signs and/or symptoms consistent with worsening or stable mild or moderate covid-19 (one of the following is required): 1. presence of at least two respiratory symptom domains (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro or 2. presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro with pulse rate ≥90 or 3. presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro with respiratory rate ≥16 and patient reported assessment that symptoms are present, the symptoms are not consistent with the subject's usual health, the symptoms interfere with daily activities, and the symptoms have worsened or remained the same relative to the previous day, as confirmed by responses to questions in the screening flu-pro. - onset of symptoms no more than 72 hours before enrollment in the trial. onset of symptoms is defined as the earlier of the first time at which the subject experienced subjective fever or any respiratory symptom (head, throat, nose, chest, or cough symptoms). - willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of the subject diary and all protocol procedures.

inclusion criteria: - male or female outpatients at least 12 years of age - presence of clinical signs and/or symptoms consistent with worsening or stable mild or moderate covid-19 (one of the following is required): 1. presence of at least two respiratory symptom domains (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro or 2. presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro with pulse rate ≥90 or 3. presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by screening flu-pro with respiratory rate ≥16 and patient reported assessment that symptoms are present, the symptoms are not consistent with the subject's usual health, the symptoms interfere with daily activities, and the symptoms have worsened or remained the same relative to the previous day, as confirmed by responses to questions in the screening flu-pro. - onset of symptoms no more than 72 hours before enrollment in the trial. onset of symptoms is defined as the earlier of the first time at which the subject experienced subjective fever or any respiratory symptom (head, throat, nose, chest, or cough symptoms). - willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of the subject diary and all protocol procedures.